101. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis
- Author
-
Simon Hughes, Rakesh Ganatra, Andrew P. Haynes, Mark Bishton, Faith Richardson, Christopher P. Fox, Eleanor James, Andrew McMillan, Eric M Bessell, and Vishakha Sovani
- Subjects
Multimodal Imaging ,Antibodies, Monoclonal, Murine-Derived ,0302 clinical medicine ,International Prognostic Index ,Recurrence ,Risk Factors ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Aged, 80 and over ,education.field_of_study ,medicine.diagnostic_test ,Remission Induction ,Age Factors ,Hematology ,Middle Aged ,Prognosis ,Treatment Outcome ,Positron emission tomography ,Vincristine ,030220 oncology & carcinogenesis ,Radiology ,Lymphoma, Large B-Cell, Diffuse ,Rituximab ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,03 medical and health sciences ,Young Adult ,medicine ,Humans ,education ,Cyclophosphamide ,Aged ,Neoplasm Staging ,Retrospective Studies ,PET-CT ,Performance status ,business.industry ,Retrospective cohort study ,medicine.disease ,Regimen ,Doxorubicin ,Positron-Emission Tomography ,Prednisone ,business ,Nuclear medicine ,Tomography, X-Ray Computed ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
The recently devised National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) appears superior to the revised IPI (R-IPI) in delineating outcome in diffuse large B-cell lymphoma. We examined the outcome of a population-based cohort of 223 consecutive patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R-CHOP-like immuno-chemotherapy between January 2005 and December 2011 by both the NCCN-IPI and R-IPI, and further stratified outcome by the achievement of both computerized tomography (CT) and positron emission tomography (PET)-CT complete remission (CR), with the latter reassessed using blinded central review by an independent nuclear medicine and radiology specialist. The NCCN-IPI was superior to the R-IPI in identifying patients at very high risk of systemic and/or central nervous system relapse. Notably, both the NCCN-IPI and the R-IPI remained strongly predictive of relapse irrespective of CT or PET-defined remission status following R-CHOP. Patients with high-risk NCCN-IPI scores (≥6) have a dismal outcome following R-CHOP therapy regardless of PET-defined response to R-CHOP. Moreover, such patients appear refractory to salvage chemotherapy and thus require alternative therapeutic approaches, although age and performance status may, for many patients, preclude the safe delivery of a primary intensified regimen. By contrast, patients with NCCN-IPI 1-5 who achieve PET-CR following R-CHOP have excellent outcomes and may merit reduced follow up frequency.
- Published
- 2015